Precision Diagnostics and the ADC Revolution
Antibody-drug conjugates are transforming cancer care, but their success depends on more precise, sensitive, and data-driven diagnostics
-
By
-
James Strachan
-
June 15, 2026
-
Clinical Scorecard: Precision Diagnostics and the ADC Revolution
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Targeting protein biomarkers on tumor cells. |
| Target Population | |
| Care Setting | Clinical laboratories utilizing IHC and computational pathology. |
Key Highlights
- Rapid growth in ADC development with ongoing clinical trials.
- Recent regulatory approvals for ADCs targeting various tumor antigens.
- Advancements in linker technology enhancing targeting precision.
Guideline-Based Recommendations
Diagnosis
- Use IHC as the preferred method for assessing ADC biomarkers.
Management
- Consider ADCs for patients with low biomarker expression levels.
Monitoring & Follow-up
- Employ computational pathology to enhance sensitivity in biomarker assessment.
Risks
- Traditional IHC may overlook patients with low expression levels.
Patient & Prescribing Data
ADCs can be effective with low levels of target protein expression.
Clinical Best Practices
- Automate IHC workflows to improve reproducibility.
- Utilize AI algorithms for assessing borderline biomarker cases.
Related Resources & Content
